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2006 were identiﬁed and categorized into two groups: with DM and without DM. 
Patients with complete insurance coverage and medication information 1-year prior 
and post the index hospitalization were included. Annual health care costs (in 2008 
US dollars) and resource utilization were compared for both groups (All p  .001 
unless otherwise stated). RESULTS: Of 12,502 patients who met the study selection 
criteria, 3,040 (24%) were diabetic and 9,462 (76%) were non-diabetic. Higher 
percent of diabetic patients had at least one all-cause rehospitalization event (49.0% 
vs 35.2%) or cardiovascular-related rehospitalization event (45.5% vs. 32.3%). Mean 
length of stay (LOS) was longer for diabetic patients during the index hospitalization 
(4.3 days vs. 3.3 days), as well as during the rehospitalization event (all-cause: 4.6 
days vs 3.3 days; cardiovascular-related: 4.6 days vs 3.2 days). In addition, patients 
with DM had more physician’s ofﬁce visits (16.3 vs. 12.4), ER visits (0.8 vs. 0.5), and 
outpatient hospital visits (9.0 vs. 7.1) during the 12-month follow-up period. Both 
cohorts had similar index ACS hospitalization costs ($32,026 vs. $29,082) but diabetic 
patients incurred higher rehospitalization costs (all-cause: $19,913 vs $10,947; car-
diovascular-related: $18,256 vs $10,093), outpatient costs ($14,836 vs. $8,617) and 
pharmacy costs ($6,105 vs. $3,921). One-year follow-up health care costs were sig-
niﬁcantly higher for patients with DM compared with those without DM ($40,853 
vs. $23,485). CONCLUSIONS: The presence of DM signiﬁcantly increases health care 
costs and resource utilization for ACS patient.
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OBJECTIVES: This study calculated 1-year total health care costs for ACS patients 
and evaluated differences based on treatment strategy for patients during their initial 
hospitalization. METHODS: Commercially insured individuals, aged 18–64, partici-
pating in a large claims database were identiﬁed by a hospitalization with an ACS 
diagnosis between January 2004 and December 2005 with a 1-year follow-up period. 
Patients who had an ACS diagnosis in the prior 12-month to their initial ACS hospi-
talization were excluded. Patients were divided into 3 groups by treatment strategy 
during the initial hospitalization: MM, PCI or CABG. Multivariate linear regression 
was performed to assess the adjusted cost differences across these 3 groups. RESULTS: 
A total of 19,617 ACS patients were identiﬁed, of which 52% (n  10,152) were 
managed by medical therapy, 40% (n  7962) by PCI and 8% (n  1539) by CABG. 
Mean length of stay and per-patient expenditures during the initial hospitalization for 
the MM, PCI and CABG groups were 1.9 days/$10,878, 3.3 days/$31,900 and 9.3 
days/$68,333, respectively. One-year follow-up costs were $25,131 for MM, $21,039 
for PCI, and $22,677 for CABG, where 46%, 42% and 46% of these costs were due 
to rehospitalization, and 4.7%, 10% and 5.9% were due to ACS-related prescription 
drug costs. Controlling for differences in demographics and clinical characteristics, 
CABG patients had approximately $52,365 greater 1-year total health care costs 
compared to MM patients (p  0.01) while PCI patients had approximately $15,952 
higher total health care costs than MM patients (p  0.01). Factors associated with 
increased costs included gender, age, comorbidities, initial hospitalization diagnosis, 
treatment strategy and prior health care costs. CONCLUSIONS: Total 1-year health 
care costs are substantial for working-aged patients newly diagnosed with ACS and 
signiﬁcantly different across the three treatment groups. Signiﬁcantly higher costs were 
observed in patients managed interventionally, particularly by CABG, with the major-
ity of these costs incurred during the initial hospitalization.
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OBJECTIVES: Resistant hypertension is deﬁned as blood pressure (BP) that remains 
above goal in spite of the concurrent use of three antihypertensive agents from differ-
ent classes. Some patients with resistant hypertension do not receive further treatment, 
potentially increasing the overall burden of disease on the health care system through 
increased health care use. To examine the burden of resistant hypertension to the UK 
health care system and explore the potential cost resulting from non-treatment of 
resistant hypertension. METHODS: The Health Improvement Network computerized 
data from 6.8 million patients in 382 practices was used to randomly select 9,000 
patients with probable or conﬁrmed resistant hypertension. Patients were character-
ized by number of therapies received according to NICE treatment guidelines (three 
therapies: step 3 vs. four or more, step 4). Blood pressure was used to classify patients 
as controlled or uncontrolled hypertension. Associations between covariates and 
patient status were examined using analysis of variance and logistic regressions. 
Pattern of care was assessed for patients in each category using descriptive statistics. 
RESULTS: Mean age of patients with hypertension included in the study was 68.8 
(SD  11.5). Among patients in step 3 at baseline, 57.2% had uncontrolled BP (mean 
BP 151/81 v. 127/73); among patients in step 4, 57.9% were uncontrolled (mean BP 
153/80 v. 136/72). After two years of follow-up, approximately 25% of patients did 
not receive treatment recommended by NICE guidelines. Older male patients with 
diabetes or kidney disease were more likely to have resistant hypertension or uncon-
trolled BP at either step 3 or 4. CONCLUSIONS: A large proportion of patients with 
hypertension do not achieve BP control despite maintaining three or more antihyper-
tensive therapies. The impact of not treating these patients with appropriate therapies 
can substantially contribute to overall burden of hypertension borne by the UK health 
care system.
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OBJECTIVES: To examine the cost impact of atrial ﬁbrillation (AFib) in patients with 
atherothrombotic diseases in a German statutory health insurance population. 
METHODS: Study design: A retrospective review of the medical, hospital and phar-
macy claims data (2004–2005) in the database of a German statutory health insurance. 
We reviewed pharmacy and medical claims data for the years 2004–2005 from an 
insurance covering about 5 Mio insurees. The data of patients suffering from cardio-
vascular diseases (myocardial infarction, stroke or PAD) were available. By using the 
documented ICD-10 codes (I48.10, I48.11, and I48.19) for hospitalizations we identi-
ﬁed patients who experienced Aﬁb during 2004 and 2005. For these patients we 
reviewed all the charges incurred for a one-year period after the initial index event on 
the basis of weekly costs and from the third party payer’s perspective. RESULTS: A 
total of 14,798 patients (mean age: 72 o 10 years) with Aﬁb could be included in the 
analysis. The majority of the patients (55%) were female. The cost for atrial ﬁbrillation 
patients for one year was a7690. The largest portion of the total cost (78%) resulted 
from the costs for hospitalization while the initial hospital stay was associated with 
30% of total costs. Approximately 100% of the study population received prescription 
drugs at an average cost of a1155 per prescription drug user. Compared to the dura-
tion before the initial diagnosis of Aﬁb, the costs increase by the factor 1.4 during the 
ﬁrst year after the event. The majority of costs one year after the event arise during 
the ﬁrst 10 weeks (approx. 50%). CONCLUSIONS: An acute Aﬁb-event in patients 
with atherothrombotic diseases represents a signiﬁcant ﬁnancial burden from the per-
spective of the statutory health insurance population. Improved management of the 
condition is needed to reduce the cost of treatment associated with AF.
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OBJECTIVES: To measure the cost of disease from the governmental perspective 
associated with body weight in people with or at high risk of atherothrombotic disease, 
using a bottom-up approach to cost estimation; and to explore the causes of any dif-
ferences found. METHODS: The health care costs of obesity were estimated from 
2819 participants recruited into the nation-wide Australian REACH Registry with 
established atherothrombotic disease or at least three risk factors for atherothrombo-
sis. Enrolment was in 2004, through primary care general practices. Information was 
collected on the use of cardiovascular drugs, hospitalisations and ambulatory care 
services. ‘Bottom-up’ costing was undertaken by assigning unit costs to each health 
care item, based on Australian Government-reimbursed ﬁgures 2006–2007. Gener-
alised-linear models were used to estimate associations between direct medical costs 
and BMI categories. RESULTS: Annual pharmaceutical costs per-person increased 
with increasing BMI, even after adjusting for gender, age, living place, formal educa-
tion, smoking status, hypertension and diabetes. Adjusted annual pharmaceutical costs 
of overweight and obese patients were higher ($83 (p  0.006) and $142 (0.001), 
respectively) than those of the normal-weight patients. This was due to patients in 
higher BMI categories receiving more pharmaceuticals than normal-weight patients 
with the same condition. There was no signiﬁcant change across the BMI categories 
in annual ambulatory care costs and annual hospital costs. CONCLUSIONS: In these 
patients with, or at high risk of, atherothrombotic disease, annual pharmaceutical 
costs were greater in patients with higher BMI, but there was no such gradient in 
annual hospital or ambulatory care costs. The greater cardiovascular pharmaceutical 
costs for patients of higher BMI remained even after adjusting for a range of demo-
graphic factors and comorbidities, and our results suggest that they are explained by 
a higher number of drugs used for the same condition. Further investigation is needed 
of the reasons for this level of drug utilisation.
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OBJECTIVES: Lost Therapeutic Beneﬁt (LTB) (receiving medication without attaining 
target BP levels) may lead to increased morbidity and mortality due to cardiovascular 
disease. Objectives of this study were to estimate the extent of LTB in patients at high 
risk of atherothrombotic events and to model the impact of attaining target BP levels 
in LTB patients on cardiovascular event rates over a two-year period. METHODS: 
The Australian REACH registry consists of 2872 high-risk patients of which 2856 
(99.4%) were followed for cardiovascular events over a two-year period. The mean 
